Related Experiment Video

Updated: Jun 13, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

CXCL12 rs1801157 Polymorphism Is Associated with Antiatherogenic Lipoprotein Subfraction Profile Independent of

İnci Deniz1,2, Ayça Türer Cabbar3, Fatma Tuba Akdeniz4

  • 1Department of Molecular Medicine, Institute of Health Sciences, Yeditepe University, Istanbul 34755, Turkey.

Journal of Clinical Medicine
|June 12, 2026
PubMed

Insights

The CXCL12 rs1801157 gene variant does not directly impact coronary artery disease risk but influences lipoprotein profiles. It promotes beneficial HDL subfractions and reduces harmful LDL particles, suggesting an indirect protective role in cardiovascular health.

Area of Science:

  • Genetics and Cardiovascular Disease
  • Lipid Metabolism and Atherosclerosis

Background:

  • Cardiovascular diseases are a leading global cause of mortality.
  • The C-X-C motif chemokine ligand 12 (CXCL12) gene is linked to atherosclerosis, but its role in lipoprotein subfractions is unclear.

Purpose of the Study:

  • To investigate the association between the CXCL12 rs1801157 single nucleotide polymorphism (SNP) and coronary artery disease (CAD) risk.
  • To evaluate the relationship between this polymorphism and low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfraction profiles.

Main Methods:

  • A case-control study involving 139 CAD patients and 125 healthy controls.
  • Genotyping via TaqMan real-time PCR and lipoprotein subfractions analyzed using the Lipoprint system.
  • Multivariable logistic and linear regression analyses adjusted for cardiovascular risk factors.

Main Results:

  • No significant differences in rs1801157 genotype or allele distributions between CAD patients and controls.
  • The polymorphism was not an independent predictor of CAD risk.
  • TT homozygous carriers showed higher large HDL and intermediate HDL levels, and lower small LDL concentrations, independent of confounders.

Conclusions:

  • The CXCL12 rs1801157 variant does not directly affect CAD susceptibility.
  • This polymorphism modulates lipoprotein quality, promoting larger HDL and reducing atherogenic small LDL particles.
  • An indirect cardioprotective role is suggested through modulation of lipid metabolism.

Keywords:
CXCL12HDLSDF-1Turkish populationcoronary artery diseaselipoprotein subfractionspolymorphismrs1801157

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...